Avangio 100 mg Injection
  1. Home
  2. Pharma Products
  3. Plasmagen BioSciences Pvt Ltd
  4. Avangio 100 mg Injection

Avangio 100 mg Injection

Avangio 100 mg Injection contains bevacizumab, a monoclonal antibody used in the treatment of several types of cancer. It works by blocking vascular endothelial growth factor (VEGF), which helps reduce the formation of blood vessels that supply tumors. The medicine is administered by intravenous infusion under the supervision of a qualified healthcare professional.

BUY NOW

Category

Avangio 100 mg Injection contains 100 mg of bevacizumab in a 4 mL vial at a concentration of 25 mg/mL. It may be used in treatment regimens for colorectal cancer, non-small cell lung cancer, kidney cancer, brain tumor, ovarian cancer, and cervical cancer. Bevacizumab binds to VEGF and inhibits tumor-associated blood vessel formation, helping to limit the blood supply available to growing tumors. The injection should be stored at 2°C to 8°C, protected from light, and should not be frozen or shaken.

Technical Specification

Specification Details
Active Ingredient Bevacizumab 100 mg
Concentration 25 mg/mL
Vial Volume 4 mL
Dosage Form Concentrate for Solution for Infusion
Route of Administration Intravenous Infusion
Storage 2°C to 8°C

Product Also Known As

Avangio 100 mg Injection, Avangio 100 mg/4 mL Injection, Avangio Bevacizumab 100 mg Injection, Bevacizumab 100 mg Injection, Bevacizumab 100 mg Infusion, Bevacizumab Oncology Injection

Related products